Emergent BioSolutions(us:EBS)

    8.08

    -0.25%

    Updated on 2024-12-23

    Open:8.03
    Close:8.08
    High:8.18
    Low:7.83
    Pre Close:8.10
    Volume:553297.00
    Amount:4.45M
    Turnover:1.02%
    Shares:54.18M
    MarketCap:437.63M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-301673041385457.49%483563
    2024-03-311513608468968.86%212977
    2023-12-311804090382078.36%184692
    2023-09-302044118132779.49%264698
    2023-06-302074568746488.20%2058104
    2023-03-312164417452187.65%3154101
    2022-12-312304669576293.21%288686
    2022-09-302474012283780.47%2478115
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Blackrock Inc.706020813.47%-2338989-24.89%
    2024-03-31Charles Schwab Investment Management Inc41513197.92%127733544.45%
    2024-03-31Vanguard Group Inc34115496.51%43691114.69%
    2024-03-31Avidity Partners Management Lp19080003.64%1908000
    2024-03-31Morgan Stanley12937022.47%583464.72%
    2024-03-31Geode Capital Management, Llc11211952.14%239762.19%
    2024-03-31Two Sigma Advisers, Lp10738002.05%-13900-1.28%
    2024-03-31State Street Corp10575932.02%-5358-0.50%
    2024-03-31Aqr Capital Management Llc10516982.01%538282104.84%
    2024-03-31Two Sigma Investments, Lp10135701.93%-25030-2.41%

    About

    Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
    Address:300 Professional Drive,Suite 400

    Market Movers